s******9
发帖数: 283 | |
c**********n
发帖数: 177 | 2 不负责任猜想下，少了三个CDR，specifity应该不如双domain的好吧，变化也少了一半
啊。。 |
s******9
发帖数: 283 | 3 你是说affinity吧？如果能够不断提高affinity呢？
【在 c**********n 的大作中提到】
: 不负责任猜想下，少了三个CDR，specifity应该不如双domain的好吧，变化也少了一半
: 啊。。
|
l*********1
发帖数: 351 | 4 structural diversity不如mAb问题不大。关键的是molecular weight不合适，再怎么
提高affinity，肿瘤部位的聚集效果不如mAb。直接的造成的问题就是biodistribution
比较烂，造成off-target effect，心脏肾脏尤为明显。Wittrup有两篇相关的文章，理
论上推到出这个结论。Darpin的实验结果也符合Wittrup的模型。所以现在Darpin也开
始做PEGylation了。。。 |
l****y
发帖数: 398 | 5 It is cleared too quickly from the body.
Lacking the constant domain means it cannot activate effector cells.
【在 s******9 的大作中提到】
: 优点大家都知道，懂行的能不能说说缺点？
|
l*********1
发帖数: 351 | 6 The half-life of nanobody can be tuned by a HSA binding module (tandem
repeats of nanobodies). Lack of cytotoxicity is definitely a major problem
of such alternative scaffolds in case of tumor treatment. Therefore,
conjugation of cytotoxic small molecules may come into play (kind of ADC
mimetics).
【在 l****y 的大作中提到】
: It is cleared too quickly from the body.
: Lacking the constant domain means it cannot activate effector cells.
|
l****y
发帖数: 398 | 7 yes, magic bullet may be the future.
【在 l*********1 的大作中提到】
: The half-life of nanobody can be tuned by a HSA binding module (tandem
: repeats of nanobodies). Lack of cytotoxicity is definitely a major problem
: of such alternative scaffolds in case of tumor treatment. Therefore,
: conjugation of cytotoxic small molecules may come into play (kind of ADC
: mimetics).
|
w********g
发帖数: 447 | 8 that's Albudab. Actually, we observed some renal lesion for Albudab. No clue
about why
【在 l*********1 的大作中提到】
: The half-life of nanobody can be tuned by a HSA binding module (tandem
: repeats of nanobodies). Lack of cytotoxicity is definitely a major problem
: of such alternative scaffolds in case of tumor treatment. Therefore,
: conjugation of cytotoxic small molecules may come into play (kind of ADC
: mimetics).
|
